| South Tulsa Vision Development | |
|
8988 S Sheridan Rd Ste D1, Tulsa, OK 74133-5035 | |
| (918) 949-4002 | |
| (918) 949-4021 |
| Full Name | South Tulsa Vision Development |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 8988 S Sheridan Rd Ste D1, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053803635 | NPI | - | NPPES |
| 200545700A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2784 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| South Tulsa Vision Development 8988 S Sheridan Rd Ste D1, Tulsa, OK 74133-5035 Ph: (918) 949-4002 | South Tulsa Vision Development 8988 S Sheridan Rd Ste D1, Tulsa, OK 74133-5035 Ph: (918) 949-4002 |
News Archive
"We have analysed emotional traits of low intensity. In this context, the higher the negative emotional traits are, the fewer risks taken by the bodies managed by the directors", Juan Bautista Delgado Garc-a, co-author of the study and researcher at UBU declares to SINC.
For the first time, researchers have inhibited the development of epilepsy after a brain insult in animals. By using gene therapy to modify signaling pathways in the brain, neurology researchers found that they could significantly reduce the development of epileptic seizures in rats.
Merck & Co have finally won the Food and Drugs Administration – FDA'S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.
Researchers at Cincinnati Children's Hospital Medical Center have discovered the first gene associated with eosinophilic esophagitis, one of a number of eosinophil-related diseases in which the body produces abnormally large amounts of white blood cells that can lead to allergy related illnesses.
› Verified 2 days ago
Amalik Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 7021 S Memorial Dr Ste 269a, Tulsa, OK 74133 Phone: 918-984-9060 | |
Midtown Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 1701 S Peoria Ave, 200, Tulsa, OK 74120 Phone: 918-599-0202 Fax: 918-599-0279 | |
Denise Roddy, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6351 E. 67th Pl., Tulsa, OK 74136 Phone: 918-497-2002 Fax: 918-497-2022 | |
Dr. Amy Wilson, OD Optometrist Medicare: Medicare Enrolled Practice Location: 7466 S Olympia Ave W, Tulsa, OK 74132 Phone: 918-447-0080 Fax: 918-447-0088 | |
Maria J Rivera, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 602 S Utica Ave, Tulsa, OK 74104 Phone: 918-585-3744 Fax: 918-535-3774 | |
Dr. Meghan Chris Shaiebly, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6465 S Yale Ave, Suite 215, Tulsa, OK 74136 Phone: 918-492-8455 Fax: 918-494-0102 | |
Ken Merchant,o.d. Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 3334 E 32nd Pl, Tulsa, OK 74135 Phone: 918-622-6244 Fax: 918-622-9126 |